After raising $125 million Rampart failed with their much-hyped non-viral gene therapy. This is a big deal because non-viral gene therapy has been pitched as the next big thing (cheaper, safer than AAV, etc), yet this is the fourth well-funded non-viral gene therapy company (SalioGen $135 mil, Intergalactic $100 mil, Generation Bio $235mil) to fail in the last couple of years. Commercial reality continues to hit hard for these pre-clinical biotechs.